Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Income from Continuing Operations (2016 - 2025)

Traws Pharma (TRAW) has disclosed Income from Continuing Operations for 14 consecutive years, with 4055000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 52.5% to 4055000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 141217000.0, a 0.24% change, with the full-year FY2024 number at 142374000.0, down 601.42% from a year prior.
  • Income from Continuing Operations was 4055000.0 for Q3 2025 at Traws Pharma, up from 5278000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 3763000.0 in Q4 2021 to a low of 123348000.0 in Q2 2024.
  • A 5-year average of 11932352.94 and a median of 4645000.0 in 2021 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 2575.66% in 2024, then skyrocketed 52.5% in 2025.
  • Traws Pharma's Income from Continuing Operations stood at 3763000.0 in 2021, then crashed by 52.38% to 5734000.0 in 2022, then increased by 22.18% to 4462000.0 in 2023, then decreased by 18.29% to 5278000.0 in 2024, then rose by 23.17% to 4055000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Income from Continuing Operations are 4055000.0 (Q3 2025), 5278000.0 (Q4 2024), and 8536000.0 (Q3 2024).